Introduction
Diabetes mellitus (DM) is the single most important cause of renal disease worldwide. 1 Type 2 DM is a growing cause of end stage renal failure worldwide. 2 With increasing prevalence of diabetes, diabetic nephropathy has become a worldwide epidemic which is the most common cause of end-stage renal disease (ESRD). 3 According to the US Renal Data System (USRDS) 2014 report (with 2012 data), 44% of total ESRD causes are diabetic nephropathy (DN). 4 Mode of treatment for DN patients is still not very clear.
Till 1990, type 2 DM patients were less likely to be referred for renal transplantation as they are older, obese and present significant comorbidities. 5 Preexisting CVD burden in diabetic patients showed high mortality in dialysis and kidney transplant patients. Consequently, proportion of patients who used to survive for a long time to experience the nephropathy risk was small. However, by analyzing kidney transplant patients from USRDS and comparing them with adult kidney waitlisted patients, Herwig-Ulf Meier-Kriesche had shown that restoring renal function by kidney transplant might lower the risk of CVD over time. 6 For transplants performed before 1988, the survival rate was significantly lower in diabetic groups as compared to other groups; but, survival of diabetic patients showed comparable results to survival of non-diabetics after adoption of a series of new procedures after 1988. 3 Individual studies have indicated that kidney transplant is a better option even for diabetic patients compared to other modes of RRT and is associated with lower risk of mortality. 7 Wolfe in his longitudinal study on dialysis patients showed that among diabetic patients, projected years of life with transplant were higher than projected years of life without transplant (on dialysis). 8 There has been little systematic exploration of how beneficial renal transplant is with pre-type 2 diabetic patients. We conducted a systematic review to summarize the outcome [ (1), prekTx vs non-prekTx (1)]. One and five year graft survival ranged from 76% to 100% and 53% to 96% respectively. 8, 4, 8, and 2 studies showed 1, 3, 5 and 10 yr patient survival respectively. Recent study with type 2 DM patients showed at 10 yrs, graft survival did not differ between Non-DM and type 2 DM but Non-DM patient survival was better (p < .001) than type 2 DM patients after RTx. At 5 yrs, patient survival ranged from 29% to 97%. Graft and patient survival did not differ between type 2 DM and Non-DM patients in three and two studies respectively. A study showed at 10 yrs, survival after RTx was significantly (p < .001) better than patients on dialysis. Preemptive transplant study reported lower adjusted graft failure and mortality risk for type 2 DM transplant recipients from living donors compared to deceased donors. Conclusion: Results from these few single center studies demonstrate the need for multicenter rigorous studies to look at long term survival of type 2 diabetes patients after renal transplant.
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renal transplantation for type 1 diabetic patients is now widely accepted, 1, 8 and results of kidney transplantation with type 2 diabetes is scarce, 1 we decided to explore survival of patients with a history of type 2 diabetes. We looked at survival of type 2 DM patients after RTx and compared survival of type 2 DM with Non-DM after RTx. Third and fourth comparisons were type 2 DM vs dialysis and preemptive KidneyTx (prekTx) vs nonprekTx. We reviewed outcome in terms of 1, 3, 5, and 10 yr graft and patients survival, immunosuppressant used and author's remarks. Additionally we looked at adverse events, death, and infections.
Methods
A comprehensive search was conducted to identify all relevant studies by using Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA). 9 Studies conducted in English language were included. Databases such as MEDLINE, EMBASE and evidence based medical reviews were searched. The detail search strategy is shown in Fig. 1 . Study was selected for further review after an agreement between the two experts.
Study selection
Study eligibility criteria were predetermined by two reviewers. Studies were appropriate for inclusion if the study reported important clinical outcomes such as patient and graft survival, infections, rejections, cardio vascular events, malignancies and cause of death in renal transplant and dialysis population. Studies with pediatric, adolescents (age < 16 yrs) and studies on multi organ or pancreas transplantation were excluded. Preference was given to studies including more than thirty participants in each treatment modality group to increase the statistical power and to minimize bias. However due to unavailability of enough published literature on renal transplant with diabetic patients, we had to compromise by including studies with sample size less than 30 in each group. The results reported here are only for single transplant. Observational/Cohort/Case-control studies from year 1980 to 2014 were included.
Risk of bias assessment
We assessed and reported risk of bias in included studies using items from the Downs and Black checklist. 10 These include items of study design, statistical analysis, and results. We included two items specifically relevant to the time-to-event analyses in these studies: (1) selected time of origin, and (2) adverse events. Two reviewers independently assessed each included study.
Data extraction
The following properties were extracted from each study: characteristics (country, data source, study period, duration of follow-up, subgroups and populations, sample size), participants' age, gender, and co morbidities, renal replacement modality (living or deceased donor: LD or DD, hemodialysis, peritoneal dialysis, etc.) and survival outcome (1 yr, 3 yr 5 yr and 10 yr survival). Other outcomes observed were: rejections, infections, cardiac events, and malignancies.
Data synthesis
The studies were few and from diverse populations; it was not possible to pool the data from these various studies. To facilitate comparison, we have presented individual study summary statistics for the variables in Tables 1a and 1b.
Results

Search result
As shown in Fig. 1 , from 147 identified citations, 78 articles were recovered for detailed evaluation of which 10 studies were suitable for this review (only type 2 DM = 2, 2,11 type 2 DM vs Non-DM = 6, 1,12-16 transplant vs Dialysis = 1, 17 and Preemptive vs non preemptive = 2). 18 Study sample size ranged from 7 to 808.
Population studied
All studies have used retrospective data. All studies were carried out in single center except one that had used data from Scientific Registry of Transplant Recipients (SRTR). Some studies had recruited type I, type II and Non-DM, 18 or IDDM, NIDM, PTDM, Non-DM and coexisting DM 14 or PreDM, or pancreas -kidney transplant 18 patients. However for this systematic review, outcome after kidney transplant related to type 2 DM, type 2 DM vs Non-DM was studied. Age of participants was 35 yrs and over. There were more male than female patients. Three studies used matched controls. Treatment of immunosuppressant was reported by 8 out of 10 studies. 1-10 yr survival of RTx patients is shown in Table 1a .
Risk of bias assessment
The risk was assessed by scoring if aims/objective, method, interventions and study design were clearly described. Patient characteristics were included. Study findings such as adverse events were reported with clarity, and study outcome was well explained.
It was observed that studies provided demographic information (90%), screening procedure (71%), method (96%), immunosuppressant (87.5%), pre transplant risk factors (RF) (58%), Studies included in the systematic review = 10 Table 1a , with type 2 DM patients, patient survival at 5 yrs was above 80%. Survival of LD was better than DD at 1 and 5 yrs.
Studies with type 2 DM vs Non-DM
Two studies each at 1 yr, 12,13 3 yr, 12,13 three studies at 5 yr 12, 14, 15 and one study at 10 yr 15 showed survival was significantly better with Non-DM patients as compared to type 2 DM patients. Two studies showed 1 yr 1,16 and 5 yr 1, 16 , and one study showed 3 yr 1 survival of type 2 DM patients was not significantly (p < .05) different from non-diabetic patients.
Study with transplant vs dialysis patients
More than 20 yrs ago a study was carried out with type 2 DM patients above 55 yrs of age. 17 Study results showed that survival was better in diabetic renal transplant patients as compared to diabetic patients maintained on dialysis. The same study showed that the short term (1 yr) outcome of non-diabetic patients with ESRD was better than survival of diabetic patients (69% vs 58%, p < .05), but no difference was observed between these two groups for 5 yr survival (18% vs 14%, ns). This short term survival was due to diabetes associated vascular complications.
Study with patients on Preemptive vs non-preemptive
We found only one study on preemptive transplant (PreKT) with type 2 DM patients. A study from US has reported significant benefit from only living donors in preKT compared to non-prekTx by showing lower mortality risk compared to recipients of diseased donors in type 2 DM (p = .001). 18 
Graft survival
Graft survival was same in type 2 DMRTx and Non-DMRTx confirming there was no significant difference at one yr [1, 12 only DD, 15, 16] , 3 yrs 1 and at 5 yrs. 1, 12, 15, 16 One study each showed significantly higher graft survival in Non-DMRTx vs type 2 DMRTx at 1 yr, 12,13 3 yr 12,13 and 5 yr. 12, 14 Death censored graft survivals of type 2 diabetics vs nondiabetics were 70% and 83% at 5 yrs and 54% and 71% at 10 yrs, respectively (p = .13), i.e. death-censored graft outcomes were similar compared with matched nondiabetic patients. 15 Preemptive transplantation presented no significant effect on graft failure among individuals with type 2 DM who received a kidney transplant. However, it showed slightly lower risk for type 2 diabetic recipients of kidney transplants from living donors (RR, 0.81; p = .09). Also, there was significantly lower adjusted risk of graft failure for transplants from living vs deceased donors (preemptive and non-preemptive) for recipients with either type 1or type 2 DM (p = .001). 18 The same study using SRTR data showed there was significantly lower adjusted risk of graft failure from living donor vs deceased donor (preemptive vs non preemptive) for recipients with type 2 DM (RR = .649, p = .001). 18 It was observed that survival (patient/graft) was better when transplant was from LD as compared to DD. 11, 12, 18 Preemptive vs non preemptive 18 Bryan N. Becke r* NA PretTx has shown benefits for type 2 DM patients with ESRD. This benefit was particularly evident with living donors (p = .007) compared to deceased donors. a : no survival difference between preemptive & non preemptive; b : preemptive survival is better than non-preemptive 3.6. Immunosuppressant 80% of the studies have discussed use of CYC (CYC_A), AZA and Prednisone. Few studies have discussed TAC, 3, 11, 15, 16 MMF 11, 16 and steroids 15 (Table 1b) .
Adverse events: Percent of infections did not differ between Type II DM and Non-DM patients except one study. 17 Rejections between Type II DM and Non-DM patients were not significantly different. One study had reported more malignancies with DM group as compared to Non-DM group. 1 Cardio vascular events were significantly more in type 2 DM vs Non-DM group 16 (not shown).
Studies have reported most common causes of death as: Cardiovascular, 13 infections, 14 malignancy 14 vascular disease, 1 death censored graft survival, 15 sepsis, 15 and MI. 15 MI, stroke and sepsis were reported more with patients on dialysis than renal transplant patients p < .0001. 17 In summary, out of 10 studies, two 1, 16 and three 1, 12, 16 studies have shown that there is no 1 and 5 yr graft and patient survival difference between type 2 DM patients and Non-DM patients respectively. Another study 15 showed that death censored graft survival between type 2 DM patients and Non-DM patients did not differ even at 10 yrs.
Study has shown graft survival was not affected, 13 but patient survival was inferior in type 2 DM compared to non-DM due to CVD and DM complications. 2, 17 RTx should be considered in type 2 DM but under certain conditions such as patients with low/ medium CVD risk and with monitoring of glycemic control. Survival is better after Rtx as compared to patient remaining on dialysis. Survival results are better in renal transplant from LRD than when renal transplant is from DD. 11 Short term survival and graft function of pre DM patients after RTx in type 2 DM patients is acceptable but lack clear evidence about long term survival (Table 1b) .
Discussion
The major objectives of this systematic review were to summarize survival after RTx of prediabetes (especially type 2 DM) vs non diabetic or dialysis or preemptive vs non preemptive recipients, but, we identified few data addressing this topic. Paucity of published information on the outcome of type 2 diabetes after renal transplant was expressed by an author from Belgium in 2001. 2 One and five year graft survival ranged from 50% to 100% and 45 to 97% respectively. One and five year patient survival ranged from 69% to 99% and 29% to 97% respectively. The patients in each study differed age wise, donor wise, matching wise and comorbidity wise. Therefore good comparison of graft or patient survival was not possible. Only one study compared long term (10 yr) survival of type 2 DM patients with non-DM patients where survival of non-DM patients was better than type 2 DM patients after renal transplantation. One of the reasons could be small number and older patients with type 2 diabetes. Registry data can be a good source. However few studies have been published using registry data.
One year average survival of DD and LD patients was similar to the survival reported by Erika Rangel. 19 The result that RTx is better than dialysis (10 yr survival is better after RTx as compared to dialysis) 9,17 is consistent with Erika Rangel's conclusion that transplant with diabetic (type 1 or 2) present higher survival rate in comparison to dialysis therapy. 19 This result was proved for patients above 55 yrs of age and the author advised to use RTx with patients without vascular complications. 17 It is also demonstrated that among RTx patients, diabetes related vascular complications, higher HbA1c levels and longer duration of DM were associated with short term (<6 mths) outcome with RTx whereas long term (>24 mths) survival was much more influenced by other age related factors such as malignancy, COPD, etc. Looking at the 5 yr survival of type 2 DM patients after RTx from this study and other studies, 1, 15, 16 it can be said that it has now improved compared to 5 yr survival of type 2 DM patients which ranged from 11% to 59% mentioned by M Hirschl in his review in 1995. 7 Results of the study on prekTx is consistent with Costas Fortuanas. 5 Unfortunately, at present, data driven benefits of prekTx have not been well documented. Results from more such studies could come up with patient specific strategies for prekTx. These results (if well documented) can be used to counsel diabetic patients.
Renal transplantation is considered the best treatment of patients with ESRD. Several studies have emphasized the benefit of RTx 17,18 and prekTx 18 for diabetic patients and for elderly patients as well. 12, 17 But these are single center studies and should be viewed with caution. Data estimating survival of type 2 DM after RTx is sparse. The outcome of patient survival after renal transplantation is little known, and incompatible results have been reported.
From these single center studies, we did find increase in the benefit of kidney transplantation over time, but, it is still uncertain about long term survival benefit of type 2 DM patients.
Registries have large data and can be a good source of conducting research on patient outcome. A well planned prospective, longitudinal cohort study explaining pre transplant rigorous screening, pre transplant treatment of cardio vascular complications, reporting donor characteristics, treatment given and the outcome together with case studies should be published. These retrospective and prospective publications should serve as a guide for future exerts.
Limitations: The main limitation was unavailability of adequate published references, especially of studies with type 2 DM patients after RTx. Secondly, almost all studies used retrospective design. Thirdly, we had to compromise with studies with small sample size. Finally, we did not look at effect of immunosuppressant on survival.
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